Marked GPR17 upregulation and/or accumulation of GPR17-expressing cells at the border of demyelinated lesions has been also observed in patients affected by MS [19,20], traumatic brain injury [21] and congenital leukoencephalopathy [22]. This evidence concerns the gene GPR17 and myeloid sarcoma.